NCT00064714 - Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Diabetes Mellitus

Interventions

DRUG

AC2993 (exenatide)

Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.

DRUG

daclizumab (immunosuppressive)

2 mg/kg intravenously infused over 30 minutes every month for 12 months

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda